Arcutis Biotherapeutics Stock In Focus After Raised Guidance

Simply Wall St.11-07 21:29

Arcutis Biotherapeutics reported third quarter 2026 revenue of US$143.92 million, raised full year 2026 net product sales guidance to a range of US$535 million to US$545 million, and has started ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681817474?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-11-07 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681817474","market":"us","top_or_hot":-1,"title":"Arcutis Biotherapeutics Stock In Focus After Raised Guidance","media":"Simply Wall St.","content":"<div>\n<p>Arcutis Biotherapeutics reported third quarter 2026 revenue of US$143.92 million, raised full year 2026 net product sales guidance to a range of US$535 million to US$545 million, and has started ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-stock-in-focus-after-raised-guidance\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcutis Biotherapeutics Stock In Focus After Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcutis Biotherapeutics Stock In Focus After Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-stock-in-focus-after-raised-guidance><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcutis Biotherapeutics reported third quarter 2026 revenue of US$143.92 million, raised full year 2026 net product sales guidance to a range of US$535 million to US$545 million, and has started ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-stock-in-focus-after-raised-guidance\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-stock-in-focus-after-raised-guidance","article_id":"2681817474","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-stock-in-focus-after-raised-guidance","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681817474","pubTimestamp":1794058150,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"Arcutis Biotherapeutics 股票在上调指导后成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":0.9},"content_text":"Arcutis Biotherapeutics reported third quarter 2026 revenue of US$143.92 million, raised full year 2026 net product sales guidance to a range of US$535 million to US$545 million, and has started enrolling patients in the Phase 3 INTEGUMENT-3 trial of ZORYVE cream 0.3% in moderate to severe atopic dermatitis. The business is positioning ZORYVE as a central growth engine, with higher selling and marketing spend, expanded leadership and board expertise, and a broader clinical program aimed at more severe disease and longer term use. Next, the focus turns to how Arcutis Biotherapeutics' investment narrative is affected by higher 2026 sales guidance for the ZORYVE franchise.  Scan how Arcutis Biotherapeutics compares with other dermatology focused plays by hunting through a curated group of 19 high quality undiscovered gems positioned around emerging treatment franchises. AdvertisementArcutis Biotherapeutics Investment Narrative Recap For a shareholder in Arcutis Biotherapeutics, the core belief is that ZORYVE can support a broader, multi indication franchise while the rest of the portfolio slowly catches up. The raised 2026 sales guidance and profitable year to date results show a business leaning into that thesis. The near term swing factor remains how effectively higher selling spend translates into sustainable prescription volume, especially with payer access still limited in Medicare Part D. The biggest risk is the heavy dependence on ZORYVE. Any slowdown in branded nonsteroidal prescription trends or tougher insurance dynamics could hit earnings, particularly while SG&A is running higher. Recent news on trials and guidance tweaks does not change that concentration risk, but it does keep attention on execution over the next few quarters. The most relevant fresh announcement for this story is the start of the Phase 3 INTEGUMENT 3 trial of ZORYVE cream 0.3% in moderate to severe atopic dermatitis. That study directly relates to the idea that Arcutis Biotherapeutics can extend ZORYVE beyond current mild to moderate use into more severe disease and longer term treatment. The trial plans to enroll about 415 participants aged 6 and up, with a 4 week double blind period followed by up to 52 weeks of open label follow up. If outcomes from this program are supportive, it could add a new indication to the same active ingredient and give the commercial team more to work with. If results underwhelm or safety flags appear, the concentration risk around ZORYVE would look more exposed and investors would likely focus more on pipeline assets such as ARQ 234. Arcutis Biotherapeutics' current analyst narrative points to forecast revenue of US$923.3 million and earnings of US$327.8 million by 2029, based on an assumed 25.8% yearly revenue growth rate and an earnings increase of about US$299.3 million from US$28.5 million today. Uncover why Arcutis Biotherapeutics' fair value indicates a 53% potential upside to its current price, which could narrow quickly. NasdaqGS:ARQT 1-Year Stock Price Chart Exploring Other Perspectives Three fair value estimates from the Simply Wall St Community span roughly US$39 to US$92 per share, so retail views on Arcutis Biotherapeutics stretch from cautious to very optimistic. When you layer that against ZORYVE concentration risk, payer constraints, and fresh clinical and leadership catalysts, it becomes clear how opinions can diverge sharply. Explore the full set of community viewpoints before deciding where you land. Explore 2 other Arcutis Biotherapeutics fair value estimates, including one that suggests it could be worth just $39.12! Decide For Yourself Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and analysis.  A great starting point for your Arcutis Biotherapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Arcutis Biotherapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to evaluate Arcutis Biotherapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Arcutis Biotherapeutics? Once you have a view on Arcutis Biotherapeutics, it can help to widen the lens and compare it with other opportunities that fit different risk and return profiles. The Simply Wall St Screener offers several focused sets of stocks that you can use to build a watchlist that matches your own style.  If you want potential upside while keeping an eye on balance sheet strength, start with a list of solid balance sheet and fundamentals (24 results) that can handle tougher conditions. If valuation discipline comes first for you, work through a 39 high quality undervalued stocks that currently screen well on both quality and price. If steadier cash returns appeal more than headline growth, filter for income ideas across a 8 dividend fortresses that might offer more predictable payouts.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681817474","isCrawlerRequest":true}